CAJ | 학술논문

目的：探讨恩度联合伊立替康治疗一线铂类耐药复发性卵巢癌的疗效及不良反应。方法选择86例对铂类耐药复发卵巢癌患者，采用恩度+伊立替康联合治疗，至少完成2个疗程后，观察临床疗效及副作用。结果总有效率为36.1%(31/86)，主要副作用为骨髓抑制、迟发性腹泻、心脏毒性，但大多数患者可以耐受。结论恩度联合伊立替康应用于治疗复发性卵巢癌，疗效值得肯定，可以改善晚期恶性肿瘤患者的生活质量，且不良反应少，比较安全，值得推广应用。
목적：탐토은도연합이립체강치료일선박류내약복발성란소암적료효급불량반응。방법선택86례대박류내약복발란소암환자，채용은도+이립체강연합치료，지소완성2개료정후，관찰림상료효급부작용。결과총유효솔위36.1%(31/86)，주요부작용위골수억제、지발성복사、심장독성，단대다수환자가이내수。결론은도연합이립체강응용우치료복발성란소암，료효치득긍정，가이개선만기악성종류환자적생활질량，차불량반응소，비교안전，치득추엄응용。
Objective To investigate the curative effect and adverse reaction of endostar combined with irinotecan treatment for ovarian cancer. Methods All 86 cases of recurrent advanced ovarian carcinoma were enrolled and treated by endostar combined with irinotecan for at least two courses period of treatment, observed the effects and the side-effects. Results Total effective rate was 36.0%(31/86,) the main side-effects were myelosuppression, tardive diarrhea, cardiotoxicity, but they were well tolerated. Conclusion The endostar combined with irinotecan treatment for recurrent advanced ovarian cancer has the best effect and can improve the quality of life for patients with advanced malignant neoplasms with less untoward effect, it is worthy of clinical promotion.